iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
“The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases.
- “The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases.
- These findings underscore ProFound AI’s transformative power to improve breast healthcare,” said Dana Brown, president and CEO of iCAD.
- Sunday, March 3, 9:30 – 11:00 am, RPS2305 – Retrospective Evaluation of Interval Breast Cancer: Can the Number of Interval Carcinomas be Reduced Utilizing AI Diagnostic Software?
- Lastly, iCAD will highlight expanded cloud platform and subscription licensing plans marking a significant advancement in deployment flexibility.